FDA Approves FLUOROURACIL — Fresenius Kabi USA, LLC

# FDA Approves Fresenius Kabi's Intravenous Fluorouracil Formulation Fresenius Kabi USA, LLC received FDA approval for its intravenous fluorouracil formulation (ANDA040278), expanding the competitive generic market for this widely-used chemotherapy agent and potentially increasing price competition in oncology treatments. The approval strengthens Fresenius Kabi's position in the injectable oncology space, a key segment for the specialty pharmaceutical and infusion services provider.